8-K: Moderna Reports Q4, Full-Year 2025 Results; Pipeline Updates

Moderna reported fourth quarter and full-year 2025 financial results, including significant net losses, while outlining 2026 revenue growth targets and key pipeline advancements despite regulatory setbacks for its flu vaccine.

Summary

• Total revenue for the fourth quarter of 2025 was $678 million, a 30% decrease compared to the same period in 2024, primarily driven by lower COVID vaccine sales volume.
• GAAP net loss for the fourth quarter of 2025 was $(826) million, resulting in a GAAP EPS of $(2.11).
• Total revenue for the full year 2025 was $1.9 billion, a 40% decrease compared to 2024, with the majority from COVID vaccine sales.
• GAAP net loss for the full year 2025 was $(2.8) billion, resulting in a GAAP diluted EPS of $(7.26).
• Moderna lowered its annual operating expenses by approximately $2.2 billion in 2025, surpassing cost-reduction targets.
• The company reiterates its plan to deliver up to 10% revenue growth and GAAP operating expense reductions in 2026.
• Moderna's influenza vaccine (mRNA-1010) filing was accepted for regulatory review in the EU, Canada, and Australia, but received a Refusal-to-File letter from the U.S. FDA, prompting a request for a Type A meeting.
• The Norovirus Phase 3 trial is fully enrolled, with a data readout expected in 2026.
• Full enrollment was achieved for the Phase 2 intismeran autogene trial in muscle invasive bladder cancer.
• Cash, cash equivalents, and investments as of December 31, 2025, were $8.1 billion, down from $9.5 billion as of December 31, 2024, including a $600 million initial draw on a $1.5 billion credit facility.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report with significant financial losses and a key regulatory setback in the U.S. for its flu vaccine, partially offset by strong cost control, pipeline advancements, and a positive 2026 revenue growth outlook.

Positives

• Fourth quarter revenue of $678 million was on the higher end of prior expectations.
• Annual operating expenses were lowered by approximately $2.2 billion in 2025, significantly surpassing cost-reduction targets.
• Net loss improved in Q4 2025 to $(826) million from $(1.1) billion in Q4 2024, and for the full year 2025 to $(2.8) billion from $(3.6) billion in 2024.
• Loss per share improved in Q4 2025 to $(2.11) from $(2.91) in Q4 2024, and for the full year 2025 to $(7.26) from $(9.28) in 2024.
• Moderna is entering 2026 with three approved products: Spikevax, mNEXSPIKE, and mRESVIA.
• Seasonal vaccines are expected to deliver up to 10% revenue growth in 2026.
• Long-term agreements for respiratory vaccines were announced with Mexico and Taiwan.
• mNEXSPIKE received regulatory approvals in Canada and Australia, and strain-updated Spikevax was authorized in the UK for the spring vaccination campaign.
• A strategic collaboration was announced with Recordati to globally commercialize Moderna's propionic acidemia candidate.
• The Norovirus Phase 3 safety and efficacy study is fully enrolled, with a data readout expected in 2026.
• The Phase 2 intismeran autogene trial in muscle invasive bladder cancer is fully enrolled.
• Positive five-year Phase 2b adjuvant melanoma data showed intismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% compared to KEYTRUDA alone.
• The propionic acidemia (mRNA-3927) registrational study reached target enrollment, with a potential data readout in 2026.
• Moderna's methylmalonic acidemia (mRNA-3705) candidate was selected by the FDA for the START pilot program, with a registrational study expected to begin in 2026.

Negatives

• Total revenue for Q4 2025 decreased 30% and for full year 2025 decreased 40% compared to the prior year, primarily due to lower COVID vaccine sales volume.
• Moderna reported significant GAAP net losses of $(826) million for Q4 2025 and $(2.8) billion for full year 2025.
• The U.S. FDA issued a Refusal-to-File letter for the seasonal flu vaccine (mRNA-1010), indicating a regulatory setback for U.S. market entry.
• Cash, cash equivalents, and investments decreased from $9.5 billion at the end of 2024 to $8.1 billion at the end of 2025, primarily driven by operating losses associated with R&D investment.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors beyond Moderna's control that could cause actual results to differ materially.
• The U.S. FDA issued a Refusal-to-File letter for the seasonal flu vaccine (mRNA-1010), creating uncertainty and potential delays for its U.S. market approval.
• Moderna is awaiting further guidance from the U.S. FDA on refiling the submission for its flu/COVID combination vaccine (mRNA-1083), which could delay its U.S. approval.
• The Norovirus Phase 3 data readout is subject to case accruals, which could impact the timing of results.
• Risks and uncertainties are described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent SEC filings.

Future Outlook

Moderna targets up to 10% revenue growth in 2026, driven by mNEXSPIKE expansion and international strategic partnerships, with an expected 50% U.S. and 50% international revenue split. The company anticipates GAAP operating expense reductions and projects year-end cash and investments between $5.5 billion and $6.0 billion. Multiple potential product approvals and late-stage clinical readouts are expected in 2026 across infectious diseases, oncology, and rare diseases, including data for Norovirus Phase 3, intismeran autogene Phase 3 melanoma, mRNA-4359 Phase 2, and propionic acidemia registrational study.

Management Comments

• "In 2025, we sharpened our commercial execution, launched our third product and brought online three international manufacturing sites, while advancing our mRNA pipeline. At the same time, we lowered our annual operating expenses by approximately $2.2 billion, significantly surpassing our cost-reduction targets." Stéphane Bancel, Chief Executive Officer of Moderna.
• "We entered the new year with strong momentum despite the continued challenging environment in the U.S., poised to deliver up to 10 percent revenue growth through mNEXSPIKE expansion and our international strategic partnerships. We look forward to delivering multiple potential product approvals and late-stage clinical readouts, while driving continued innovation across our mRNA platform." Stéphane Bancel, Chief Executive Officer of Moderna.

Industry Context

StockSavvy.ai notes that Moderna's continued reliance on COVID vaccine sales, despite diversification efforts, reflects the broader challenge for vaccine developers in a post-pandemic market. The regulatory setback for the flu vaccine in the U.S. highlights the competitive and stringent nature of vaccine approvals, especially against established players. The advancements in oncology and rare diseases, particularly the positive melanoma data, position Moderna to potentially expand beyond infectious diseases, aligning with a trend among biotech firms to leverage platform technologies across multiple therapeutic areas.

Comparison to Industry Standards

• Moderna's 40% revenue decline in 2025 contrasts with some established pharmaceutical companies that have diversified revenue streams, though it is common for companies heavily reliant on a single product (like COVID vaccines) to see significant fluctuations post-peak.
• The 49% reduction in recurrence or death risk for adjuvant melanoma with intismeran autogene + KEYTRUDA is a strong clinical outcome, comparable to or exceeding efficacy seen in some other novel immuno-oncology combinations, such as those involving PD-1 inhibitors in similar settings. Merck's KEYTRUDA (pembrolizumab) alone has shown significant benefits in adjuvant melanoma, and Moderna's combination appears to enhance this.
• The Refusal-to-File letter from the U.S. FDA for the seasonal flu vaccine (mRNA-1010) indicates a hurdle that competitors like Sanofi (Fluzone), GSK (Fluarix), and CSL Seqirus (Flucelvax) have successfully navigated for their established flu vaccines, suggesting Moderna faces a steeper climb for U.S. market entry in this mature segment.

Management Changes

Stakeholder Impact

• Shareholders face significant net losses and a declining cash position, but cost reductions and pipeline advancements offer future potential. Regulatory setbacks for the flu vaccine in the U.S. introduce uncertainty.
• Employees may experience continued scrutiny of staffing and operational efficiency due to ongoing portfolio prioritization and cost discipline.
• Customers will see broader access to Moderna's vaccines through new product approvals and geographic expansion, such as mNEXSPIKE in Canada and Australia, and agreements with Mexico and Taiwan.
• Regulatory authorities are actively engaged with Moderna, as evidenced by interactions with the FDA regarding the Refusal-to-File letter, Type A meeting request, and the START pilot program.
• Partners like Merck and Recordati are impacted by continued collaboration on intismeran autogene and a new strategic collaboration for the propionic acidemia candidate, respectively, demonstrating active and expanding partnerships.

Next Steps

• Conduct a Type A meeting with the U.S. FDA to understand the path forward for the seasonal flu vaccine (mRNA-1010).
• Await further guidance from the U.S. FDA on refiling the submission for the flu/COVID combination vaccine (mRNA-1083).
• Anticipate potential approvals for the seasonal flu vaccine (mRNA-1010) in Europe, Canada, and Australia starting in 2026.
• Expect a data readout for the Norovirus Phase 3 safety and efficacy study in 2026.
• Anticipate potential Phase 3 adjuvant melanoma data for intismeran autogene in 2026.
• Expect a potential Phase 2 data readout for mRNA-4359 in 2026.
• Anticipate a potential data readout for the propionic acidemia (mRNA-3927) registrational study in 2026.
• Expect the registrational study for methylmalonic acidemia (mRNA-3705) to begin in 2026.
• Hold the Moderna Annual Meeting of Shareholders on Wednesday, May 6, 2026.
• Host an Analyst Day on November 12, 2026.

Key Dates

Recommendation

While Moderna demonstrated strong cost control and pipeline advancements, particularly in oncology and rare diseases, the significant revenue decline and substantial net losses for 2025, coupled with the U.S. FDA's Refusal-to-File for a key seasonal flu vaccine, present considerable headwinds. The 2026 outlook for revenue growth and expense reduction is positive, but the company's cash burn and regulatory uncertainties warrant a cautious "hold" stance until clearer paths to profitability and U.S. market access for new products emerge.

Keywords

Moderna, MRNA, financial results, Q4 2025, full-year 2025, revenue, net loss, EPS, mRNA vaccines, pipeline, COVID vaccine, flu vaccine, norovirus vaccine, oncology, rare diseases, intismeran autogene, regulatory review, FDA, cost reduction, operating expenses, cash position